Vacunas最新文献 - Book学术

Would senior citizens get vaccinated against RSV? Exploratory analysis using a novel survey instrument

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/j.vacun.2024.11.003

Mohammad Abu-Ghosh , Dareen Saleh , Joud Al-Haddad , Leen Sabbah , Raghad Alnusairat , Muna Barakat , Malik Sallam

{"title":"Would senior citizens get vaccinated against RSV? Exploratory analysis using a novel survey instrument","authors":"Mohammad Abu-Ghosh , Dareen Saleh , Joud Al-Haddad , Leen Sabbah , Raghad Alnusairat , Muna Barakat , Malik Sallam","doi":"10.1016/j.vacun.2024.11.003","DOIUrl":"10.1016/j.vacun.2024.11.003","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the attitude of senior citizens towards the newly approved respiratory syncytial virus (RSV) vaccines using a novel survey instrument specifically tailored for this purpose.</div></div><div><h3>Material and methods</h3><div>Based on a literature review on vaccination attitude towards respiratory viruses (SARS-CoV-2 and influenza), 15 items were tested for content, face, and construct validity. Data collection nvolved face-to-face interviews among individuals aged 50 years or older in Jordan during May–June 2024. Construct validity was assessed using exploratory factor analysis (EFA) based on principal component analysis.</div></div><div><h3>Results</h3><div>A total of 231 respondents formed the final sample. The EFA showed that 5 constructs explained 71.9% of the variance in attitude to RSV vaccination. These constructs were labeled Fear, Information, Accessibility, Benefit, and Conspiracy. The acceptance of a safe and effective RSV vaccine if provided free-of-charge was observed among 55.4% of the participants (<em>n</em> = 128), while 16.0% were hesitant (<em>n</em> = 37), and 28.6% were resistant (<em>n</em> = 66). Applying the 5 RSV vaccine attitude constructs, demographic data, and vaccination history into the multivariate analysis, a higher RSV vaccine acceptance was found among elderly individuals with lower monthly incomes, a history of higher vaccine uptake, agreement with the Benefit construct, and disagreement with the Fear construct.</div></div><div><h3>Conclusions</h3><div>This study developed an initial survey instrument to assess the attitudes of senior citizens towards the newly approved RSV vaccines. Further testing across diverse settings is necessary to evaluate the barriers and motivators influencing attitude to RSV vaccination. This effort is crucial to reduce the burden of RSV disease among the elderly.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 1","pages":"Article 100384"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tosferina como enfermedad reemergente. Situación epidemiológica en la provincia de Salamanca

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/j.vacun.2024.10.001

Ana María Haro Pérez , Mar Jiménez Rodríguez , Saray Martín Monteagudo , Nieves Gutiérrez Zufiaurre

{"title":"Tosferina como enfermedad reemergente. Situación epidemiológica en la provincia de Salamanca","authors":"Ana María Haro Pérez , Mar Jiménez Rodríguez , Saray Martín Monteagudo , Nieves Gutiérrez Zufiaurre","doi":"10.1016/j.vacun.2024.10.001","DOIUrl":"10.1016/j.vacun.2024.10.001","url":null,"abstract":"<div><h3>Objetives</h3><div>Describe the evolution and characteristics of confirmed pertussis cases during the last 5 years, detect possible underreporting, study the burden of the pertussis on healthcare system at the current time and assess the effect of vaccination.</div></div><div><h3>Material and methods</h3><div>Retrospective observational study of pertussis cases reported in the province of Salamanca and patients diagnosed with pertussis by PCR by the Microbiology of the reference hospital, from January 2018 to March 2024.</div></div><div><h3>Results</h3><div>A total of 58 cases of pertussis were detected, 42 correspond to the period November 2023 – March 2024. Thirty-five (60.3%) were reported as EDO. A total of 48% were not vaccinated, and the average time from the last dose of the vaccine to diagnóstico in vaccinated people was 136.3 days (SD 40) in children under 1 year of age and 605.3 days (SD 407) in the 1–4 year-old group. Twelve cases (20.7%) required hospitalization (3 under 1 year old, 1 under 2 years old, 1 under 7 years old, 2 between 34 and 64 years old and 5 over 65 years old), of which 7 (58.3%) were not vaccinated.</div></div><div><h3>Conclusions</h3><div>The epidemiological evolution of pertussis shows a significant increase in 2023–2024, both in childhood and in adulthood, despite detecting underreporting. Vaccination is one of the fundamental strategies for the prevention of pertussis, the risk of which increases with the time elapsed since the last dose of vaccine, so vaccination coverage should be promoted in all age groups and in specific groups of risk, with the introduction of diphtheria-tetanus-pertussis in booster doses.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 1","pages":"Article 100379"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introducción de la numeración de artículos en Vacunas

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/S1576-9887(25)00012-3

引用次数: 0

Las nuevas vacunas genéticamente atenuadas frente al virus de la poliomielitis

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/j.vacun.2024.10.003

Jordi Reina , Julia Viana-Ramírez

{"title":"Las nuevas vacunas genéticamente atenuadas frente al virus de la poliomielitis","authors":"Jordi Reina , Julia Viana-Ramírez","doi":"10.1016/j.vacun.2024.10.003","DOIUrl":"10.1016/j.vacun.2024.10.003","url":null,"abstract":"<div><div>There are two types of vaccines available against polio virus: the inactivated (Salk, IPV) and the oral/attenuated (Sabin, OPV). Live vaccines are highly effective in inducing protective immunity against certain infections, also favoring the cessation of their epidemic spread. There are three wild serotypes of the polio virus, however currently two of them, serotype 2 and 3, are considered eradicated so that the only one that still circulates in endemic countries is serotype 1. One of the problems of OPV, which cannot occur with IPV, is its possible reversion to the wild form, circulating as vaccinal poliovirus (cOPV) and its transmission to unvaccinated people, giving rise to paralytic processes associated with the vaccine. To avoid this phenomenon, new oral polio vaccines (nOPV-c1) with greater safety and less reversion have been developed by modifying and introducing a series of genetic modifications in the RNA of the virus. Different studies have shown that children who received OPV2-c1 presented a higher degree of attenuation and thermostability and a highly significant decrease in the ability to affect the nervous system and develop severe neurovirulence and possible post-vaccination polio. These studies establish the pathogenic and molecular bases in the most vulnerable child population that allowed the use of this new genetically attenuated vaccine in population vaccination campaigns.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 1","pages":"Article 100381"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A narrative review on the white spot syndrome virus and the perspective of vaccine development

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/j.vacun.2024.11.001

Susithra Priyadarshni Mugunthan , Nivetha Loganathan , Balamurugan Shanmugaraj , Harish Mani Chandra

引用次数: 0

COVID-19 story: Entry and immune response

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/j.vacun.2024.10.002

Ali Mohammed Ashraf , Marwan Y. Al-Maqtoofi , Ahmed A. Burghal

{"title":"COVID-19 story: Entry and immune response","authors":"Ali Mohammed Ashraf , Marwan Y. Al-Maqtoofi , Ahmed A. Burghal","doi":"10.1016/j.vacun.2024.10.002","DOIUrl":"10.1016/j.vacun.2024.10.002","url":null,"abstract":"<div><div>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic of the coronavirus disease 2019 (COVID-19) that emerged in December 2019 in Wuhan city, China. Understanding the SARS-CoV-2 entry, invasion and infection mechanism is crucial for vaccine development. The immune system is divided into 2 parts: the innate immune system and the adaptive immune system, and they work in essential and powerful ways for SARS-CoV-2 managing and reducing COVID-19 infections. Spike proteins (S) of SARS-CoV-2 are a pivotal key during the viral invasion of the host cells. Cell surface receptors facilitate binding and then membrane fusion for virus endocytosis and causing infection. Host cells are covered with receptors for viral S proteins binding, such as the human angiotensin-converting enzyme 2 receptor. The innate immune responses initiate after viral antigen detection via a set of pathogen recognition receptors, including the Toll-like receptors (TLRs) family. TLRs are largely inducible in most body cell types. After SARS-CoV-2 antigen recognition, cellular sensors stimulate the production of interferons and inflammatory cytokines, which are crucial for controlling viral replication and dissemination. The cellular and humoral responses of the adaptive immune system antibody-producing B-cells, CD4+ T-cells to evoke the immune response, and CD8+ T-cells to kill infected cells. This review outlines the process of virus entry and detection by pattern recognition receptors and antiviral defence by both innate immunity and adaptive immunity for developing immunological memory that can help in vaccines and understanding the immune response to SARS-CoV-2.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 1","pages":"Article 100380"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The growing threat of monkeypox and the urgent need for vaccination in Pakistan

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/j.vacun.2024.09.005

Alisha Saleem , Ashar Masood Khan , Danish Faheem , Bina Fawad

引用次数: 0

Evaluation of the effect of melatonin on patients with COVID-19 admitted to ICU: A double-blind randomized clinical trial

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/j.vacun.2024.09.004

Mahmoud Ganjifard , Shokouh Ghafari , Adeleh Sahebnasagh , Mahboubeh Esmaeili , Ali Reza Amirabadizadeh , Azadeh Ebrahimzadeh , Parvin Askari , Razieh Avan

{"title":"Evaluation of the effect of melatonin on patients with COVID-19 admitted to ICU: A double-blind randomized clinical trial","authors":"Mahmoud Ganjifard , Shokouh Ghafari , Adeleh Sahebnasagh , Mahboubeh Esmaeili , Ali Reza Amirabadizadeh , Azadeh Ebrahimzadeh , Parvin Askari , Razieh Avan","doi":"10.1016/j.vacun.2024.09.004","DOIUrl":"10.1016/j.vacun.2024.09.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This research aims to examine the efficacy of melatonin as an adjuvant therapeutic agent for COVID-19 patients in the intensive care unit.</div></div><div><h3>Methods</h3><div>A randomized, double-blind, placebo-controlled investigation was conducted on a group of hospitalized COVID-19 patients. Individuals were allocated into 2 groups: one group received a combination of 18 mg of melatonin and standard treatment for 14 days; the other group received a placebo in addition to standard treatment. Patients were evaluated at the beginning of the study as well as the 7th and 15th days to analyze changes in clinical symptoms, P/F ratio, and inflammatory markers.</div></div><div><h3>Results</h3><div>The study included patients with an average age of 57.80±17.96 years, with an equal gender representation. The average length of hospital stay was 19.83±4.45 days. Hypertension and diabetes were commonly observed comorbidities. There were no significant differences in the demographic characteristics between the 2 groups (<em>P</em>  >.05).</div></div><div><h3>Conclusion</h3><div>Our study's findings suggested that melatonin is unlikely to significantly affect the clinical status of COVID-19 patients.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 1","pages":"Article 100377"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143547993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monitoring of hepatitis B infection in the elderly population of eastern Iran

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/j.vacun.2024.08.002

Abdol Sattar Pagheh , Effat Alemzadeh , Eisa Nazar , Mitra Moodi , Farshad Sharifi , Ebrahim Miri-Moghaddam , Mohamad Taghi Rahimi , Soroush Mohammadi , Masood Ziaee

{"title":"Monitoring of hepatitis B infection in the elderly population of eastern Iran","authors":"Abdol Sattar Pagheh , Effat Alemzadeh , Eisa Nazar , Mitra Moodi , Farshad Sharifi , Ebrahim Miri-Moghaddam , Mohamad Taghi Rahimi , Soroush Mohammadi , Masood Ziaee","doi":"10.1016/j.vacun.2024.08.002","DOIUrl":"10.1016/j.vacun.2024.08.002","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to investigate the prevalence of HBV infection and its associated risk factors in the elderly in Birjand.</div></div><div><h3>Materials and methods</h3><div>The present study was a part of the community-based prospective cohort study. Subjects over 60 years of age were assessed using standard questionnaires and blood factors. The samples were tested for HBsAg by enzyme-linked immunosorbent assay.</div></div><div><h3>Results</h3><div>Of 542 elderly people living in Birjand, 11 cases (2.03%) were positive. The median age of patients with HBsAg positive and negative was 69 (IQR: 63–77) years and 67 (IQR: 63–74) years, respectively. The results of the multiple logistic regression model showed that fatty liver disease was significantly associated with having hepatitis B (AOR (95% CI)=5.50 (1.16, 25.88)) (<em>p</em>  >.05).</div></div><div><h3>Conclusions</h3><div>Even though there were only a few positive cases, leading to a non-significant report, it is crucial to emphasize the clinical significance and health and well-being of elderly individuals contracting hepatitis B. This information can be valuable in devising suitable disease management strategies for this age group.</div></div>","PeriodicalId":53407,"journal":{"name":"Vacunas","volume":"26 1","pages":"Article 100373"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143547992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence and COVID-19 vaccine hesitancy

Vacunas Pub Date : 2025-01-01 DOI: 10.1016/j.vacun.2024.08.001

Sara Kamal Shahsavar , Arman Alinezhad , Masoud Keikha

引用次数: 0